Rigel Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Rigel Pharmaceuticals Stock Forecast and Price Target
If Rigel Pharmaceuticals's stock price reached the average yearlong target of $2.50 given by three well-known analysts in recent months, there would be a potential upside of approximately 121.24% from its last closing price in April, 2024. This potential increase is based on a high estimate of $15.00 and a low estimate of $1.65. If you're looking for information on Rigel Pharmaceuticals stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.
121.24% Upside
Rigel Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Rigel Pharmaceuticals's Price has seen an increase, rising from $0.00 to $0.00. This represents a growth of 100.00%. Analysts predict that Rigel Pharmaceuticals's Fair Value will increase in the upcoming year, reaching $1.22. This would represent an increase of 100.00%. Over the next nine years, experts predict that Rigel Pharmaceuticals's Fair Value will grow at a rate of 100.00%.
Rigel Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Rigel Pharmaceuticals's Revenue has seen an increase, rising from $108.62M to $116.88M. This represents a growth of 7.60%. Analysts predict that Rigel Pharmaceuticals's Revenue will increase in the upcoming year, reaching $138.52M. This would represent an increase of 18.51%. Over the next eight years, experts predict that Rigel Pharmaceuticals's Revenue will grow at a rate of 160.89%.
.jpg)
Rigel Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Rigel Pharmaceuticals's EBITDA has decreased by 31.91%, from $-28.27M to $-19.25M. For the next year, 1 analysts project Rigel Pharmaceuticals's EBITDA to drop by 34.03%, reaching $-12.70M. By 2030, professionals believe that Rigel Pharmaceuticals's EBITDA will decrease by 549.16%, reaching $86.46M – a concerning trend for the company.
Rigel Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Rigel Pharmaceuticals's EBIT has fallen from $-28.97M to $-20.49M – a 29.27% decrease. According to 4 prominent analysts, Rigel Pharmaceuticals's EBIT will fall by 4.20% in the next year, reaching $-19.63M. By 2030, professionals believe that Rigel Pharmaceuticals's EBIT will decrease by 610.54%, reaching $104.61M – a concerning trend for the company.
Rigel Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Rigel Pharmaceuticals's EPS has seen an increase, rising from $-0.18 to $0.00. This represents a growth of 100.00%. Analysts predict that Rigel Pharmaceuticals's EPS will increase in the upcoming year, reaching $-0.13. This would represent an increase of 100.00%. Over the next nine years, experts predict that Rigel Pharmaceuticals's EPS will grow at a rate of 100.00%.
Site Navigation
.jpg)